NBIX director sells 15,000 shares after option exercise
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions.
Rhea-AI Filing Summary
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised 15,000 Non-Qualified Stock Options at a strike price of $47.89 per share and on the same day sold 15,000 common shares in open-market transactions. The weighted average sale price was $157.6507 per share, with individual trades ranging from $155.51 to $158.68. These sales were executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026. Following the transactions, Pops directly holds 34,480 shares of Neurocrine common stock. The options exercised were granted on May 20, 2016 and are scheduled to expire on May 20, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 15,000 shares ($1.65M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
POPS RICHARD F
Role
Director
Sold
15,000 shs ($2.36M)
Approx. gross sale proceeds
$2.36M
Approx. exercise cost
$718K
Approx. pre-tax spread
$1.65M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $47.89 | $718K |
| Sale | Common Stock | 15,000 | $157.6507 | $2.36M |
Holdings After Transaction:
Non-Qualified Stock Option — 0 contracts (Direct);
Common Stock — 34,480 shares (Direct)
Footnotes (3)
- F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on February 13, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.51 to $158.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026.
Key Figures
Shares sold: 15,000 shares
Weighted average sale price: $157.6507/share
Options exercised: 15,000 options
+4 more
7 metrics
Shares sold
15,000 shares
Open-market sale of common stock on May 15, 2026
Weighted average sale price
$157.6507/share
Sales in range $155.51–$158.68 on May 15, 2026
Options exercised
15,000 options
Non-Qualified Stock Options converted into common stock
Option strike price
$47.89/share
Exercise price for Non-Qualified Stock Options granted May 20, 2016
Shares held after transactions
34,480 shares
Direct common stock holdings following May 15, 2026 trades
Rule 10b5-1 plan adoption date
February 13, 2026
Plan governing broker-executed sales
Option expiration date
May 20, 2026
Non-Qualified Stock Options expire 10 years after grant
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title": "Non-Qualified Stock Option""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sales price financial
"Represents a weighted average sales price per share. These shares were sold in multiple transactions"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
What insider transactions did NBIX director Richard F. Pops report?
Richard F. Pops exercised 15,000 Non-Qualified Stock Options at $47.89 per share and sold 15,000 Neurocrine common shares. The sales occurred in open-market transactions on May 15, 2026 at a weighted average price of $157.6507.
What options did Richard F. Pops exercise in this NBIX Form 4?
He exercised 15,000 Non-Qualified Stock Options convertible into 15,000 Neurocrine common shares at a strike price of $47.89 per share. The options were granted on May 20, 2016 and are scheduled to expire on May 20, 2026, according to the footnotes.
How were the vesting and expiration terms of Pops’ NBIX options described?
The Non-Qualified Stock Options were granted on May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. The filing notes these options will expire ten years from grant, on May 20, 2026, if not exercised earlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
